JAAD Online
Reply to: “COVID-19 vaccination in IMID patients receiving rituximab: A personalized regimen should be formulated”

https://doi.org/10.1016/j.jaad.2022.03.042Get rights and content

Cited by (0)

Authors Pahalyants and Murphy are cofirst authors.

Funding sources: None.

Key words: COVID-19 vaccination; immune-mediated inflammatory diseases; rituximab.

Reprints not available from the authors.

IRB approval status: This study received approval from the Massachusetts General Hospital Institutional Review Board.

View Abstract